Stock Titan

ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

Of patients whose plans changed, 87% had treatment de-escalated based on negative MRD results; the assay detected ctDNA ...